Resources

Download Brochure
Contact Us
Europe, Middle East, Africa / Product Areas / Interventional Cardiology/Radiology / Peripheral Interventions / Pulsar-18 T3

Pulsar™-18 T3 Self-Expanding Stent

A unique combination of 3 technologies

Pulsar™-18 T3 is the first clinically-proven thin strut stent mounted on a tri-axial low profile (4F) delivery system. It is indicated for use in patients with atherosclerotic disease of the superficial femoral, proximal popliteal and infrapopliteal arteries and for the treatment of insufficient results after Percutaneous Transluminal Angioplasty (PTA), e.g. residual stenosis and dissection.*

Pantera Lux product image

Product Highlights

Circles icon

Tri-axial system with braided shaft

4F icon

Low profile delivery system

Struts icon

Thin struts, low COF

Circles icon

Tri-axial system with braided shaft

Accurate stent deployment

Unique tri-axial shaft design

The outer stabilizing shaft isolates the retractable shaft from friction caused by the introducer valve to ensure accurate stent deployment.

Pulsar Stent Deployment diagram
4F icon

Low profile delivery system

Smaller puncture site area1

4F low profile - improved acute outcomes* vs. 6F3

Potential for safer, faster and simpler procedures than 6F

  • Clinically proven lower access site complication rates3
  • Shorter compression time3
  • 45% smaller puncture site than 6F1
  • No need for a closure device3
  • Potential for ambulatory treatment
Pulsar-18 T3 Smaller Puncture site graphic
Struts icon

Thin struts, low COF

Lower risk of restenosis2

140 μm thin struts - thinner than leading brands1

Thinner struts for lower Chronic Outward Force (COF)1

Pulsar-18 T3 Outward Force Chart
Pulsar-18 T3 Strut thickness in perspective

Thinner struts and lower COF make a difference:*

  • Lower risk of restenosis2
  • Reduced vessel injury and inflammation2
  • Faster endothelialization4,5

Pulsar-18 T3 Vessel Response

Clinical Highlights

4EVER

82.7% FTLR at 24 months

Physician-initiated trial investigating the safety of the full 4F endovascular treatment approach of infra inguinal arterial stenotic disease

See More

TASC D

86.0% FTLR at 12 months

Twelve months effectiveness analysis of the Pulsar™-18 self-expanding nitinol stent in patients with critical lim ischemia

See More

BIOFLEX PEACE

89.3% FTLR at 24 months

Evaluating the safety and efficacy of the Pulsar™-18 self-expanding stent for femoropopliteal lesions with optional drug-coated balloon angioplasry in a real-world, all-comers population

See More

Product Overview


Stent
Catheter type OTW
Recommended guide wire 0.018”
Stent Material Nitinol
Strut thickness 140 μm
Strut width 85 μm
Stent coating proBIO™ (Amorphous Silicon Carbide)
Stent markers 6 gold markers each end
Sizes ø 4.0 - 7.0 mm; L: 20 - 200 mm
Shaft 4F, hydrophobic coating, tri-axial
Usable length 90 cm and 135 cm

Stent Catheter length 90 cm
ø (mm) (Stent length mm)
20 30 40 60 80 100 120 150 170 200
4F 4 430437 430438 430439 430440 430441 430442 430443 430444 430445 430446
5 430447 430448 430449 430450 430451 430452 430453 430454 430455 430456
6 430457 430458 430459 430460 430461 430462 430463 430464 430465 430466
7 430467 430468 430469 430470 430471 430472 430473 430474 430475 430476
Stent Catheter length 135 cm
ø (mm) (Stent length mm)
20 30 40 60 80 100 120 150 170 200
4F 4 430477 430478 430479 430480 430481 430482 430483 430484 430485 430486
5 430487 430488 430489 430490 430491 430492 430493 430494 430495 430496
6 430497 430498 430499 430500 430501 430502 430503 430504 430505 430506
7 430507 430508 430509 430510 430511 430512 430513 430514 430515 430516

IFU Link

Refer to this IFU link for a copy of the Instructions for Use and for a complete listing of the indications, contraindications, warnings and precautions.

References:

FTLR = Freedom from Target Lesion Revascularization.


  1. Data on file
  2. Zhao HQ. Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009 Jul;32(4):720-6
  3. Bosiers M et al. 4-French - compatible endovascular material is safe & effective in the treatment of femoropopliteal occlusive disease: Results of the 4EVER Trial. ENDOVASC THER 2013; 20: 746-756
  4. Koskinas C. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. JACC 2012 10;59(15):1337-49
  5. Koppara T. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv. 2015 8(6):e002427
  6. Funovics M. Correlation between chronic outward force (COF) and neointimal hyperplasia in self-expanding nitinol stents in swine in clinically relevant oversizing ranges. Presented at: LINC, Jan 26, 2017; Leipzig, Germany.

Teleflex, the Teleflex logo, proBIO and Pulsar are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S and/or other countries. All other names are the trademarks or registered trademarks of their respective owners. Refer to this IFU link for a copy of the Instructions for Use and for a complete listing of the indications, contraindications, warnings and precautions. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries.

© 2025 Teleflex Incorporated. All rights reserved.